Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Cancer Clear all

Conditions: Liver Cancer
Interventions: Not listed
Lead sponsor: Pathfinder Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Invasive Ductal Carcinoma, Invasive Lobular Carcinoma, Ductal Carcinoma
Interventions: Indocyanine Green; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Atezolizumab, Biospecimen Collection, Carboplatin, Lumpectomy, Mastectomy, Paclitaxel; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 9 more

Conditions: Breast Cancer
Interventions: Transcutaneous vagus nerve and acupuncture point stimulation; Device
Lead sponsor: The Healing Consciousness Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Meadowbrook, Pennsylvania

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer
Interventions: Vorinostat and Tamoxifen; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Accuboost APBI; Device
Lead sponsor: Brown University; Other
Eligibility: 50 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: La Jolla, California • Lakeland, Florida • Providence, Rhode Island

Conditions: Bladder Cancer
Interventions: Apaziquone, Placebo; Drug · Other
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Non Muscle Invasive Bladder Cancer
Interventions: CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside; Biological · Other
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: La Jolla, California • Orange, California • Tampa, Florida + 9 more

Conditions: Invasive Breast Cancer
Interventions: Fulvestrant, Anastrazole; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
Interventions: Endocrine Therapy, Biopsy of breast, Neratinib, Biospecimen Collection, Mammogram, Magnetic Resonance Imaging, Breast Surgery, Ultrasound; Procedure · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 5
States / cities: Atlanta, Georgia • Pittsburgh, Pennsylvania • Nashville, Tennessee + 2 more

Conditions: Invasive Bladder Cancer Stage II
Interventions: Rapamycin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive Tumor, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-negative Breast Carcinoma
Interventions: Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Decitabine, Pembrolizumab; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 4
States / cities: Edgewood, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more

Conditions: Invasive Breast Cancer
Interventions: Doxil, Paclitaxel, Cyclophosphamide, Avastin; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Urinary Bladder Neoplasms
Interventions: nivolumab, Placebo, Bacillus Calmette-Guérin (BCG); Drug · Other · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Chicago, Illinois • The Bronx, New York

Conditions: Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
Interventions: Cisplatin, Doxorubicin, Methotrexate, Pegfilgrastim, Pembrolizumab, Radical Cystectomy, Vinblastine Sulfate; Drug · Biological · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ductal Breast Carcinoma, Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Postmenopausal, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions: Broccoli Sprout Extract, Laboratory Biomarker Analysis, Pharmacological Study, Placebo; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 21 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Cancer
Interventions: cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, tamoxifen citrate; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2006
U.S. locations: 106
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 87 more

Conditions: Bladder Cancer
Interventions: BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)), PANVAC; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Bethesda, Maryland • New Brunswick, New Jersey

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: gemcitabine hydrochloride, pemetrexed disodium; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 121
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 88 more

Conditions: Cancer Head Neck, Metastatic Cancer, Metastatic Lung Cancer
Interventions: adnectin 18F-BMS-986192 Head and Neck Cancer, adnectin 18F-BMS-986192 Brain Metastases; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pancreatic Cancer, Liver Cancer
Interventions: Ultrasound scan of the pancreas, Ultrasound scan of the Liver, Reference ultrasound; Device · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cervical Cancer
Interventions: iodinated contrast dye, computed tomography, magnetic resonance imaging, gadopentetate dimeglumine; Drug · Procedure · Radiation
Lead sponsor: American College of Radiology Imaging Network; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 2
States / cities: Morristown, New Jersey • New York, New York

Conditions: Cystic Fibrosis, Colorectal Cancer, Adenoma
Interventions: Stool tests; Procedure
Lead sponsor: University of Washington, the Collaborative Health Studies Coordinating Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 26
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 21 more

Conditions: Prostate Cancer
Interventions: Genomic and Histological Evaluation; Genetic
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 35 Years to 85 Years · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures

Intraoperative Imaging of Breast Cancer With Indocyanine Green

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

MindVybe tVNS/APS for Wellbeing in Breast Cancer Survivors

A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Broccoli Sprout Extract in Treating Patients With Breast Cancer

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases

Ultrasound Monitoring of Abdominal Soft Tissue

MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients

Colorectal Cancer Screening in Cystic Fibrosis

Non-Invasive Biomarkers in Prostate Cancer Disease Management